What is stereotactic body radiotherapy?
Stereotactic body radiotherapy (SBRT) is a highly precise form of external beam radiotherapy that delivers very high doses of radiation to a small target in just a few treatments. It is also called stereotactic ablative radiotherapy (SABR). The word ablative reflects the aim: to destroy the tumour completely, much as surgery or heat-based treatments would, but without any cuts.
Conventional radiotherapy usually spreads a moderate total dose over many weeks of daily sessions. SBRT instead gives a much larger dose per session, typically in 1 to 8 treatments over one to two weeks.
Many beams are aimed at the tumour from different angles. Each beam on its own is relatively weak, but where they meet, the dose is intense. Healthy tissue around the target receives far less.
This precision depends on modern imaging, careful immobilisation and techniques that account for movement, such as breathing. SBRT is used in the body (lungs, liver, prostate, spine, kidneys, pancreas and lymph nodes). The equivalent technique for the brain is called stereotactic radiosurgery and is covered in a separate article.
A brief history
Stereotactic techniques were first developed for the brain in the mid-twentieth century, using a rigid frame fixed to the skull. Applying the same idea to the body was harder, because organs move with breathing and digestion. In the 1990s, teams in Sweden and Japan began treating lung and liver tumours with body frames and image guidance. Since then, CT scanners built into treatment machines, breath-tracking systems and MRI-guided machines have made SBRT widely available.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | External beam radiotherapy (stereotactic) |
| Main uses | Early lung cancer, prostate cancer, liver and kidney tumours, spinal and other metastases |
| How it is given | Machine delivers precisely shaped beams while you lie still on a couch |
| Number of sessions | Usually 1-8 |
| Session length | About 15-60 minutes |
| Hospital stay | None; outpatient treatment |
| Common side effects | Tiredness, mild skin changes, local effects depending on the area treated |
2. How it works
Why a high dose per session matters
Radiation damages DNA inside cancer cells. When a very high dose is given in a single session, it seems to cause additional damage to the small blood vessels that feed the tumour and may help stimulate the immune system. This makes SBRT especially effective at controlling the treated tumour, even for cancers that respond less well to standard radiotherapy.
Key technical elements
| Element | What it does |
|---|---|
| Immobilisation | Moulded cushions or body frames keep you in exactly the same position |
| Planning scans | CT, often with 4D CT to show how the tumour moves with breathing; MRI or PET may be added |
| Motion management | Breath-hold, abdominal compression, gating or tracking keep the beam on target |
| Image guidance | Scans on the treatment couch before every session check the position |
| Fiducial markers | Tiny gold seeds placed near some tumours to help targeting |
| Steep dose fall-off | High dose inside the target, much lower dose just outside |
Machines used
SBRT can be delivered on a modern linear accelerator, a robotic arm system (CyberKnife), a tomotherapy unit or an MRI-guided machine. The choice depends on what the hospital has and the tumour’s location rather than one being clearly better than the others.
3. Who it is for
Conditions treated
| Condition | Role of SBRT |
|---|---|
| Non-small cell lung cancer | Early-stage tumours, especially in people who cannot have or do not want surgery |
| Lung adenocarcinoma | Small peripheral tumours |
| Lung squamous cell carcinoma | Small tumours in people unfit for surgery |
| Prostate adenocarcinoma | Low and intermediate-risk disease given in about 5 sessions |
| Hepatocellular carcinoma | Tumours unsuitable for surgery or ablation |
| Clear cell renal cell carcinoma | Small kidney tumours in people unfit for surgery; metastases |
| Pancreatic ductal adenocarcinoma | Selected locally advanced tumours, usually in trials or specialist centres |
| Colorectal adenocarcinoma | Limited lung or liver metastases |
| Invasive ductal carcinoma | Limited metastases from breast cancer |
Oligometastatic disease
Some people have cancer that has spread to only a few places, often defined as up to 3 or 5 sites. This is called oligometastatic disease. Treating every site with SBRT, alongside standard treatment, may help some people live longer. Careful selection is important, and this approach is still being tested in larger trials.
SBRT for the spine
Metastases in the spine can cause pain and threaten the spinal cord. Spinal SBRT gives a high dose to the affected bone while keeping the dose to the spinal cord, only millimetres away, within safe limits. It may be chosen when longer control is wanted, for tumours that respond poorly to standard radiotherapy, or when a spot has already been treated before. It needs specialised planning and is not suitable if the cord is already being squeezed.
SBRT for the prostate
For prostate cancer, SBRT condenses a course that once took around 7-8 weeks into about 5 sessions. Tiny gold markers or a gel spacer between the prostate and rectum may be used to improve accuracy and protect the bowel. Hormone therapy may be added for higher-risk disease.
Who is suitable
| Usually suitable | Usually less suitable |
|---|---|
| Small tumours, often under 5 cm | Large tumours |
| Tumours away from sensitive structures | Tumours touching the bowel, gullet or main airways |
| Able to lie still for up to an hour | Unable to lie flat or still |
| Limited number of metastases | Widespread disease (unless for symptom relief) |
4. Before treatment
| Step | Why it is done |
|---|---|
| Consultation | Discuss aims, alternatives and side effects |
| Biopsy | Often, but not always, to confirm cancer |
| Staging scans | PET-CT or other scans to make sure the cancer is limited |
| Breathing tests | For lung treatment, to check lung reserve |
| Fiducial markers | Placed in some liver, pancreas or prostate cases |
| Planning session | Immobilisation devices made and scans taken in the treatment position |
| Treatment planning | Physicists and doctors design the plan over 1-2 weeks |
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Arrival | Change into a gown if needed |
| 2. Positioning | You lie in your custom immobilisation device |
| 3. Imaging | A scan on the couch checks the tumour position; small adjustments are made |
| 4. Treatment | The machine moves around you; you feel nothing |
| 5. Breathing | You may be asked to hold your breath or breathe gently |
| 6. Finishing | You can go home straight afterwards and usually drive |
| 7. Further sessions | Often every other day until the course is complete |
Treatment itself is painless. The most uncomfortable part is usually lying still on a firm couch, sometimes with your arms above your head.
6. Side effects and risks
| Side effect | Area treated | Notes |
|---|---|---|
| Tiredness | Any | Usually mild and short-lived |
| Chest wall pain or rib fracture | Lung tumours near the ribs | Can occur months later |
| Lung inflammation (pneumonitis) | Lung | Cough or breathlessness, usually 1-6 months after; treatable with steroids |
| Urinary and bowel irritation | Prostate | Frequency, urgency, mild rectal irritation |
| Nausea | Liver, pancreas, upper abdomen | Usually short-lived |
| Liver function changes | Liver | Monitored with blood tests |
| Pain flare or vertebral fracture | Spine | Steroids may reduce pain flare |
| Skin redness | Any | Usually mild |
Serious complications
Because the dose is so high, injury to nearby sensitive organs can be serious. Tumours close to the centre of the chest, the bowel or the spinal cord need especially careful planning. In the SABR-COMET trial of people with a few metastases, about 3 in 66 people treated with SABR died from treatment-related causes, a reminder that the benefits and risks must be weighed carefully (Palma et al., 2019).
7. Results and outlook
| Study | Main finding |
|---|---|
| RTOG 0236, early lung cancer in people unfit for surgery (55 evaluable) | The treated tumour was controlled in about 98% at 3 years, and 3-year survival was about 56% (Timmerman et al., 2010) |
| CHISEL, stage 1 lung cancer (101 people) | The cancer returned in the treated area in 14% after SABR compared with 31% after several weeks of standard radiotherapy (Ball et al., 2019) |
| SABR-COMET, 1-5 metastases (99 people) | Adding SABR to standard care improved median survival from 28 to 41 months (Palma et al., 2019) |
| SABR-COMET long-term results | Five-year survival was about 42% with SABR versus about 18% with standard care alone (Palma et al., 2020) |
What the evidence means
For small, early lung cancers in people who cannot have surgery, SBRT is now a standard treatment with very high rates of local control. For oligometastatic disease, early trials are encouraging, but larger studies are ongoing to identify who benefits most. In many other situations, SBRT offers a short, convenient course that fits around other treatments.
8. Recovery and aftercare
After treatment
| Tip | Why |
|---|---|
| Rest when tired | Tiredness can build for a week or two |
| Keep active | Gentle exercise helps energy levels |
| Report new cough, fever or breathlessness | Possible lung inflammation after lung treatment |
| Report chest wall pain | Possible rib irritation |
| Drink plenty of fluids | Helps urinary symptoms after prostate treatment |
Follow-up
| Check | Timing |
|---|---|
| First review | Usually 4-12 weeks after treatment |
| Scans | Every 3-6 months at first |
| Blood tests | For example PSA for prostate cancer or liver tests for liver tumours |
Understanding follow-up scans
After lung SBRT, scans often show scarring or inflammation around the treated area that can look like a growing tumour. These changes can last for months or years. Your team will compare scans over time, and sometimes use PET scans or a biopsy, before deciding whether cancer has returned.
Coping with uncertainty
Living with cancer that has spread, even to only a few places, can bring worry about what comes next. Regular scans may cause anxiety in the days before results. Talking to your specialist nurse, joining a support group or seeing a counsellor can help.
Daily life
Most people carry on with normal activities during SBRT. You can usually work, drive and look after yourself. Because the course is short, it fits well around family and work commitments.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Surgery | Standard for fit people with early lung cancer and many other localised tumours |
| Conventional radiotherapy | Larger tumours or those near sensitive structures |
| Radiofrequency and microwave ablation | Small liver, kidney and lung tumours |
| Brachytherapy | Prostate and some other cancers |
| Proton beam therapy | Selected tumours near critical structures |
| Palliative radiotherapy | Simple short courses for symptom relief |
| Active monitoring | Some very slow-growing tumours |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is SBRT the same as CyberKnife? | CyberKnife is one machine that can deliver SBRT; others are used too |
| Will I be radioactive? | No, external radiotherapy does not make you radioactive |
| Does it hurt? | No; treatment is painless |
| Can SBRT be repeated? | Sometimes, depending on previous doses |
| Will I lose my hair? | Only if the treated area includes hair-bearing skin, which is uncommon |
| Can I have it with immunotherapy or chemotherapy? | Often, with timing planned by your team |
| Is it as good as surgery? | For fit people with early lung cancer, surgery remains standard; trials comparing the two are ongoing |
11. Questions to ask your care team
- What is the aim of SBRT for me: cure, control or symptom relief?
- Why is SBRT recommended over surgery or other options?
- How many sessions will I need?
- Which side effects are most likely in my case?
- Will I need fiducial markers?
- How will my follow-up be organised?
- Are there clinical trials I could join?
Resources
- Ball, D. et al. (2019) ‘Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial’, The Lancet Oncology, 20(4), pp. 494-503.
- Palma, D.A. et al. (2019) ‘Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial’, The Lancet, 393(10185), pp. 2051-2058.
- Palma, D.A. et al. (2020) ‘Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial’, Journal of Clinical Oncology, 38(25), pp. 2830-2838.
- Timmerman, R. et al. (2010) ‘Stereotactic body radiation therapy for inoperable early stage lung cancer’, JAMA, 303(11), pp. 1070-1076.
- National Cancer Institute (2026) External Beam Radiation Therapy for Cancer. Available at: https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/external-beam (Accessed: October 2026).
- National Cancer Institute (2026) Non-Small Cell Lung Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.